Status:
TERMINATED
Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborating Sponsors:
National Cancer Institute (NCI)
Rutgers Cancer Institute of New Jersey
Conditions:
Unspecified Adult Solid Tumor - Protocol Specific
Breast Cancer - Female
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is an open label, dose escalation study to determine the safety and tolerability and maximum tolerated dose of pazopanib combined with weekly paclitaxel and carboplatin in patients with advanced ...
Detailed Description
This is an open label, dose escalation study to determine the maximum tolerated dose (MTD) of pazopanib combined with weekly paclitaxel and carboplatin in patients with advanced solid tumors. There wi...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of a solid malignancy with advanced disease that has relapsed, that is refractory to standard therapies, or for which there is not standard therapy, or for which the patient opts not to receive standard therapy.
- At the recommended phase II dose level, triple-negative breast cancer defined as ER-negative, PR-negative, and HER2-negative, will be enrolled and another 10 patients with a solid malignancy who would benefit from a paclitaxel and carboplatin-based regimen, will also be enrolled.
- Male or female ≥ 18 years of age
- Able to swallow and retain oral medications
Exclusion
- Major surgery within last 28 days or cytotoxic chemotherapy, biologic therapy, investigational agents, or radiotherapy within last 21 days. Patients who have completed therapy with mitomycin C or nitrosurea will have to wait 42 days.
- More than 3 prior lines of cytotoxic chemotherapy for metastatic disease
Key Trial Info
Start Date :
September 17 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 29 2016
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT01407562
Start Date
September 17 2010
End Date
March 29 2016
Last Update
September 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08903